Home Corporate Overview Board Management Founders
What's New

September 25, 2014
PPD Exercises Option to Acquire Remaining Interest in X-Chem, Inc.
With numerous strategic partnerships underway, X-Chem emerges as a leading biotechnology company focused on drug discovery

June 11, 2014
X-Chem Enters into Multi-Target Collaboration with Pfizer Inc.
Goal to Establish Novel Small Molecule Leads Using X-Chem's Discovery Engine Fueled by its Proprietary Library of More Than 100 Billion DNA-encoded Compounds

March 31, 2014
Discovering Small Molecule Compounds through The DNA Encoded Library Technology
CEOCFO Article

February 24, 2014
Bigger is Better
BioCentury Article

February 13, 2014
X-Chem Licenses Epigenetic Drug Discovery Program to Bayer Pharma AG
Discovery of Novel and Selective Small Molecules for Epigenetic Target Enabled by XChem's DNA-Encoded Library of 100 Billion Compounds

February 4, 2014
X-Chem First Biotech to Exceed 100 Billion Compounds with its Unique and Proprietary Small Molecule DNA-Encoded Library
Company publishes breakthrough DNA-encoding strategy in peer-reviewed chemistry journal (article)

January 10, 2014
X-Chem and PsyBrain Establish Partnership to Discover New Psychiatric Medicines
New company founded by world-renowned leaders arising out of an X-Chem Collaboration with Academic CNS Drug Development Clinicians

October 3, 2013
X-Chem Enters Expanded Global Drug Discovery Collaboration with AstraZeneca
Establishes X-Chem as a Key Partner in AstraZeneca's Drug Discovery Strategy

September 24, 2013
X-Chem Achieves Early Success in Collaboration with AstraZeneca, Licenses Three Drug Discovery Programs
X-Chem's Technology Platform Enables Rapid Discovery of Progressable Lead Series Against Protein-Protein Interaction (PPI) and Other Challenging Targets

A letter from Founder and CEO, Richard W. Wagner, Ph.D.:


Our Vision

X-Chem, Inc. is a privately held biotechnology company based in Waltham, Massachusetts, established in 2009 to apply its innovative drug discovery capabilities to the generation of novel small molecule therapeutics.

Our Goal

We aspire to increase the number of "shots on goal" per target. Our chemical strategy can be applied broadly to both challenging and other targets in any therapeutic area.

Our Team

We have built a strong team of leading experts with proven track records in innovative drug discovery and biotechnology partnering.

Competitive Advantage

Our discovery platform capitalizes on multiple proprietary innovations in library design, screening methodology, and informatics that underlie its exceptional performance.

Achievements and Partnerships

We have demonstrated our success both internally and with external partnerships by tackling some of the most difficult, intractable targets such as:

Within three years of being founded, X-Chem has established collaborations with some of the leading pharmaceutical companies in the world, including but not limited to F. Hoffmann-LaRoche Ltd. and AstraZeneca AB. X-Chem also maintains partnerships with several academic centers and institutions.

We invite you to contact us to learn more about our innovative strategies for small molecule discovery and discuss how we can collaborate.

Richard W. Wagner, Ph.D.
Founder and CEO, X-Chem, Inc.